Jazz Pharmaceuticals came into this Q3 2026 earnings print with a bruised 90 day share performance and a rich P/E, yet the stock ripped 7.1% higher to about US$229.74 on the first trading day after results. The headline is not revenue, even though sales reached about US$1.24b. The real shock is earnings per share swinging from a profit in Q2 to a basic loss of US$7.47 as a large hit ran straight through the income statement. That clash between a sharp profit squeeze and a vigorous price jump is what matters for you now.
Love the sharp price reaction in Jazz Pharmaceuticals but concerned about that sudden earnings loss running through the income statement? Compare this setup with companies screened for sturdier fundamentals in our list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$1,243m vs. US$1,126.1m (up about 10%)
- Net Income/Loss (Excl. Extra Items, Q3 2026 vs. Q3 2025): loss of US$483.4m vs. profit of US$251.4m (swung into a large loss)
- Basic EPS (Q3 2026 vs. Q3 2025): loss of US$7.47 per share vs. profit of US$4.14 per share (moved from positive to sharply negative)
- R&D Pipeline Breadth (Selected Programs, Q3 2026 vs. Q3 2025): Phase I: 5 vs. 9, Phase II: 4 vs. 5, Phase III: 3 vs. 6, Pre-Registration: 1 vs. 0, Approved Products: 1 vs. 1 (pipeline mix shifted with fewer early and late stage programs and one product in pre-registration)
Jazz just posted record revenue and a breakout Ziihera launch. Ask Charlie what makes Jazz’s new cancer drug launch stand out.
Jazz bull case: oncology and epilepsy execution on trial
The upbeat story says Jazz Pharmaceuticals can turn Ziihera and rare epilepsy into long term growth engines that reshape the business mix.
"The main thing that has to go right is successful execution on Jazz Pharmaceuticals’ oncology and rare epilepsy pipeline, including Ziihera’s expansion into additional tumors, Modeyso’s frontline data readout, and the integration of ABS-1230 into the broader epilepsy platform."
Record Q3 revenue of US$1.24b, raised full year guidance, first commercial Ziihera sales and the closing of Actio with ABS-1230 moving through Phase Ib/II all point to milestones being ticked. The basic loss reflects the IPR&D hit from Actio, so earnings optics are messy even as the pipeline footprint clearly widens.
Jazz bear case: IP, competition and sentiment getting real
Skeptics worry that patent cliffs, rival drugs and a fragile shareholder base will undercut that oncology and epilepsy story.
"Patent expirations and potential generic competition, especially for Xyrem and high sodium oxybate products, are still a live issue and could erode Jazz Pharmaceuticals' sleep franchise revenues and compress net margins if pricing and volumes come under pressure."
Sleep and neuroscience still anchor results, with Xywav and Epidiolex driving much of the US$1.24b quarter. That helps counter the patent fear for now. Yet a swing to a US$483.4m underlying loss and the Actio driven GAAP hit show how dependent Jazz Pharmaceuticals is on heavy investment, while oncology competition and earlier post earnings share price declines keep the risk case alive despite the latest 7.1% rebound.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.
Hunt For Mispriced Earnings Stories
Jazz Pharmaceuticals just showed how a messy quarter can still attract fresh attention from investors. The real opportunity could be finding stocks where expectations and business trends appear out of sync.
- Company 1 - 42% below our estimate - target higher margin protective films and installation services as new manufacturing capacity reshapes its cost base and product mix.
- Company 2 - 43% below our estimate - sell large format digital displays and software as customers upgrade scoreboards, transport signage and youth sports venues to richer visual systems.
- Company 3 - 35% below our estimate - run refurbishment centers and a recommerce platform as trade in subsidies and greener consumption policies channel more used devices into formal resale.
Three companies from the same screener. Open every one of the 34 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com